PFC
BBIO icon

Phocas Financial Corp’s BridgeBio Pharma BBIO Stock Holding History

Phocas Financial Corp’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-55,298
Closed -$922K – 212
2021
Q4 		$922K Sell
55,298
-1,294
-2% -$54.7K 0.12% 142
2021
Q3 		$2.65M Buy
56,592
+584
+1% +$31.3K 0.34% 112
2021
Q2 		$3.41M Buy
+56,008
New +$3.2M 0.43% 97

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Phocas Financial Corp's BBIO Position: Q1 2022 in Review

Phocas Financial Corp sold out of BridgeBio Pharma (BBIO) in Q1 2022, closing a stake of 55,298 shares — an estimated $922K sold.

Phocas Financial Corp first reported a position in BBIO in Q2 2021 and held it in 3 quarters. The position peaked at $3.41M in Q2 2021. 178 funds tracked by Wall St. Rank hold BBIO as of Q1 2022.

  • Phocas Financial Corp reported no remaining BridgeBio Pharma position as of Q1 2022 after selling out during the quarter.
  • Phocas Financial Corp sold 55,298 BridgeBio Pharma shares in Q1 2022, an estimated $922K.
  • Phocas Financial Corp first reported a position in BridgeBio Pharma in Q2 2021 and held it in 3 quarters.
  • Phocas Financial Corp's BridgeBio Pharma position peaked at $3.41M in Q2 2021.
  • 178 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2022.

Based on Phocas Financial Corp's 13F filing for Q1 2022, filed 25 May 2022.